Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity

Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioural output of acute d-amphetamine

(2014) A. Polissidis et al.   BEHAVIOURAL BRAIN RESEARCH

Amphetamine-induced release of dopamine in primate prefrontal cortex and striatum: striking differences in magnitude and timecourse

(2014) Hank P. Jedema et al.   JOURNAL OF NEUROCHEMISTRY

Propentophylline increases striatal dopamine release but dampens methamphetamine-induced dopamine dynamics: A microdialysis study

(2014) B. Gough et al.   NEUROCHEMISTRY INTERNATIONAL

Involvement of glutamatergic and GABAergic transmission in MK-801-increased gamma band oscillation power in rat cortical electroencephalograms

(2014) T. Hiyoshi et al.   NEUROSCIENCE

Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data

(2014) Kazunari Yoshida et al.   SCHIZOPHRENIA RESEARCH

Amphetamine stimulates movement through thalamocortical glutamate release

(2013) Omar S. Mabrouk et al.   JOURNAL OF NEUROCHEMISTRY

Selective serotonin 2A receptor antagonism attenuates the effects of amphetamine on arousal and dopamine overflow in non-human primates

(2013) Kevin S. Murnane et al.   JOURNAL OF SLEEP RESEARCH

Phosphodiesterase 10A inhibitor MP-10 effects in primates: Comparison with risperidone and mechanistic implications

(2013) Subramaniam Uthayathas et al.   NEUROPHARMACOLOGY

Phosphodiesterase 10A controls D1-mediated facilitation of GABA release from striato-nigral projections under normal and dopamine-depleted conditions

(2013) Dalila Mango et al.   NEUROPHARMACOLOGY

Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model

(2013) Carina J. Bleickardt et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating

(2013) Jodi E. Gresack et al.   PSYCHOPHARMACOLOGY

Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: An analysis of the CATIE data

(2013) Hiroyoshi Takeuchi et al.   SCHIZOPHRENIA RESEARCH

Orexin Receptor Antagonists Differ from Standard Sleep Drugs by Promoting Sleep at Doses That Do Not Disrupt Cognition

(2013) J. M. Uslaner et al.   Science Translational Medicine

Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia

(2012) Izzat T. Raheem et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey

(2012) Sean M. Smith et al.   NEUROPHARMACOLOGY

Measuring the construct of executive control in schizophrenia: Defining and validating translational animal paradigms for discovery research

(2012) Gary Gilmour et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

(2011) Paul Morgan et al.   DRUG DISCOVERY TODAY

Acute administration of typical and atypical antipsychotics reduces EEG gamma power, but only the preclinical compound LY379268 reduces the ketamine-induced rise in gamma power

(2011) Nigel C. Jones et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Gamma synchrony: Towards a translational biomarker for the treatment-resistant symptoms of schizophrenia

(2011) Michael J. Gandal et al.   NEUROPHARMACOLOGY

The evolution of antipsychotic switch and polypharmacy in natural practice — A longitudinal perspective

(2011) Chisa Tsutsumi et al.   SCHIZOPHRENIA RESEARCH

Aligning strategies for using EEG as a surrogate biomarker: A review of preclinical and clinical research

(2010) Steven C. Leiser et al.   BIOCHEMICAL PHARMACOLOGY

Advanced Research on Dopamine Signaling to Develop Drugs for the Treatment of Mental Disorders: Biochemical and Behavioral Profiles of Phosphodiesterase Inhibition in Dopaminergic Neurotransmission

(2010) Akinori Nishi et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to d-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons

(2009) Florence Sotty et al.   JOURNAL OF NEUROCHEMISTRY

Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia

(2009) S. M. Grauer et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death

(2009) Wayne A. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation

(2008) S. Threlfell et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

(2008) C. J. Schmidt et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS